At a glance
ClinicalIndex Comparison Record- ✓Stage I, II, or III primary breast, ovarian, or non-small cell lung cancer
- ✓Planning to start taxane-based chemotherapy (docetaxel for breast/ovarian or paclitaxel for breast/lung/ovarian) within 14 days of registration
- ✓Able to complete Patient-Reported Outcome instruments in English or Spanish and willing to complete all scheduled assessments
- ✓Willing to submit required specimens for translational medicine
- ✕Stage IV disease
- ✕Prior receipt of taxane (paclitaxel, docetaxel, protein-bound paclitaxel), platinum (cisplatin, carboplatin, oxaliplatin), vinca alkaloid, or bortezomib-based chemotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
In Brief
An observational study evaluating Chemotherapy, Functional Assessment, and 1 other intervention for Anatomic Stage I Breast Cancer AJCC v8 and 45 related conditions. Active but no longer recruiting, targeting 1,336 participants across 169 sites in 4 countries.
Signals
Detailed Summary
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
Study Details
Timeline
Arms & Interventions
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
Interventions
Given chemotherapy regimen
Functional and sensory clinician assessments
Patient and physician reported responses